EASI试验:单粒1600mg 5-氨基水杨酸片剂方案治疗溃疡性结肠炎的临床评估
这项开放标签随机对照IV期试验纳入178例稳定缓解的溃疡性结肠炎患者,比较单粒1600mg与三粒800mg 5-氨基水杨酸片剂方案12个月。两组依从率无显著差异(P=0.32),复发数量与复发比例亦无差异,单粒低剂量方案可作为传统三粒方案的可行替代。
要点
- 单粒1600mg与三粒800mg 5-ASA方案依从性无显著差异(P=0.32)。
- 两组复发数量及复发比例无差异,依从性与治疗分组均非复发显著预测因素。
- 单粒低剂量方案可作为稳定缓解UC患者的可行替代方案。
核心结论
- 单粒1600mg 5-ASA方案在保持缓解率方面与常规三粒800mg方案相当,可作为可行替代。
研究设计与样本
- 开放标签随机对照IV期试验,纳入178例溃疡性结肠炎患者(每组89例),按1:1随机分组,治疗12个月。
- 入组患者需在5-ASA治疗下稳定缓解至少2个月,且无影响依从性的合并疾病。
主要发现
- 单粒1600mg组漏服患者比例较少(24.5 vs. 26.5)。
- 两组复发数量及复发比例无差异,依从性与治疗分组均非复发的显著预测因素。
临床怎么用
- 对稳定缓解的轻中度溃疡性结肠炎患者,可考虑单粒1600mg 5-ASA方案以简化用药。
局限性
- 开放标签设计可能影响依从性评估;入组患者为稳定缓解且无影响依从性合并疾病,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 5-Aminosalicylate (5-ASA) is recommended for the treatment of mild-to-moderate ulcerative colitis (UC). However, adherence may be low; poor adherence is associated with an increased risk for flares. AIM: To investigate whether a regimen of a single 1600 mg tablet of 5-ASA improves adherence with preserved remission rates compared to a conventional regimen of three 800 mg tablets. METHODS: We enrolled 178 patients with UC (89 per group) in this open-label randomised controlled phase IV trial. Patients had to have stable remission on 5-ASA for at least 2 months and no concomitant diseases that could affect compliance. We randomised patients (1:1) to either receive Asacol 1600 mg single tablet or Asacol 2400 mg (three tablets of 800 mg once daily) for 12 months. Patients were assessed five times during the 12 months, where medicine was delivered and received, blood and stool samples were collected and symptom scores were determined. RESULTS: Eighty-two patients taking a single tablet and 78 taking three tablets were adherent (p = 0.32). Fewer patients in the 1600 mg group missed doses (24.5 vs. 26.5). There was no difference in the number of relapses or proportions experiencing relapse. Neither adherence nor treatment group was a significant predictor of relapse. CONCLUSION: The single-tablet lower dose treatment could be a feasible alternative to the conventional three-tablet regimen. TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov (ID NCT04133194) and approved by The Danish Medicine Agency and The National Committee on Health Research Ethics (EudraCT 2019-002070-31).
引用
- Nordestgaard RLM, Lo B, Bergstrøm R, et al. Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5-Aminosalicylate for Ulcerative Colitis-The EASI Trial. Aliment Pharmacol Ther. 2025. PMID: 40955556. doi:10.1111/apt.70375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。